Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2026)

Kymera Therapeutics has reported Change in Accured Expenses over the past 8 years, most recently at -$7.2 million for Q1 2026.

  • Quarterly Change in Accured Expenses rose 38.33% to -$7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Mar 2026, up 50.53% year-over-year, with the annual reading at $7.4 million for FY2025, 76.72% up from the prior year.
  • Change in Accured Expenses was -$7.2 million for Q1 2026 at Kymera Therapeutics, down from $13.7 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $13.7 million in Q4 2025 and troughed at -$15.4 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $2.7 million (2024), against an average of $709235.3.
  • Year-over-year, Change in Accured Expenses plummeted 1069.36% in 2022 and then soared 578.32% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.8 million in 2022, then surged by 139.02% to $6.8 million in 2023, then skyrocketed by 32.81% to $9.0 million in 2024, then skyrocketed by 51.43% to $13.7 million in 2025, then plummeted by 152.77% to -$7.2 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Change in Accured Expenses are -$7.2 million (Q1 2026), $13.7 million (Q4 2025), and $664000.0 (Q3 2025).